GENINCODE PLC LS -01 - Asset Resilience Ratio

Latest as of December 2025: 2.86%

GENINCODE PLC LS -01 (9PL) has an Asset Resilience Ratio of 2.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GENINCODE PLC LS -01 working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€68.00K

≈ $79.50K USD Cash + Short-term Investments

Total Assets

€2.38 Million

≈ $2.78 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how GENINCODE PLC LS -01's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see GENINCODE PLC LS -01 balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down GENINCODE PLC LS -01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read GENINCODE PLC LS -01 balance sheet liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€68.00K	2.86%
Total Liquid Assets	€68.00K	2.86%

Asset Resilience Insights

Limited Liquidity: GENINCODE PLC LS -01 maintains only 2.86% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

GENINCODE PLC LS -01 Industry Peers by Asset Resilience Ratio

Compare GENINCODE PLC LS -01's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Medpace Holdings Inc NASDAQ:MEDP	Diagnostics & Research	0.00%
Chemclin Diagnostics Co. Ltd. A SHG:688468	Diagnostics & Research	15.34%
Genetic Signatures Ltd AU:GSS	Diagnostics & Research	60.91%
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Healius Ltd AU:HLS	Diagnostics & Research	0.06%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%

Annual Asset Resilience Ratio for GENINCODE PLC LS -01 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for GENINCODE PLC LS -01.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.86%	€68.00K ≈ $79.50K	€2.38 Million ≈ $2.78 Million	+0.80pp
2024-12-31	2.07%	€55.00K ≈ $64.30K	€2.66 Million ≈ $3.11 Million	+1.06pp
2023-12-31	1.00%	€42.00K ≈ $49.10K	€4.19 Million ≈ $4.89 Million	+0.87pp
2022-12-31	0.14%	€16.00K ≈ $18.71K	€11.80 Million ≈ $13.79 Million	+0.11pp
2021-12-31	0.03%	€4.00K ≈ $4.68K	€15.21 Million ≈ $17.78 Million	--

pp = percentage points

About GENINCODE PLC LS -01

F:9PL Germany Diagnostics & Research

Market Cap

$6.16 Million

€5.27 Million EUR

Market Cap Rank

#28302 Global

#2430 in Germany

Share Price

€0.01

Change (1 day)

+0.00%

52-Week Range

€0.00 - €0.08

All Time High

€0.45